CY1109669T1 - Χρηση υποκατεστημενων παραγωγων της ινδολιζινης 1,2,3 για τη θεραπεια νοσων που σχετιζονται με μια παθολογικη χοριοειδη αγγειογενεση - Google Patents
Χρηση υποκατεστημενων παραγωγων της ινδολιζινης 1,2,3 για τη θεραπεια νοσων που σχετιζονται με μια παθολογικη χοριοειδη αγγειογενεσηInfo
- Publication number
- CY1109669T1 CY1109669T1 CY20091101327T CY091101327T CY1109669T1 CY 1109669 T1 CY1109669 T1 CY 1109669T1 CY 20091101327 T CY20091101327 T CY 20091101327T CY 091101327 T CY091101327 T CY 091101327T CY 1109669 T1 CY1109669 T1 CY 1109669T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alk
- alkyl
- alkoxy
- coor
- pathological
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Η παρούσα εφεύρεση αφορά στη χρήση υποκατεστημένων παραγώγων ινδολιζίνης 1, 2, 3, για την παρασκευή φαρμάκων χρήσιμων στη θεραπεία ασθενειών οι οποίες σχετίζονται με μια παθολογική χοριοειδή αγγειογένεση, τα οποία παράγωγα αντιστοιχούν στον ακόλουθο γενικό χημικό τύπο (I) : στον οποίο το R1 αντιπροσωπεύει -ΟΗ, αλκοξυ(C1-C5), καρβοξυ, αλκοξυκαρβονυλ(C2 - C6), -NR5R6, -NH-SΟ2-Alk, -NH-SO2Ph, -NH-CO-Ph, -N(Alk)-CO-Ph, -NH-CO-NH-Ph, -NH-CO-Alk, -NH-CΟ2-Alk, -O-(CH2)n-cAlk, -O-Alk-COOR7, -O-Alk-O-R8, -O-Alk-OH, -O-Alk-C(NH2):NOH, -O-Alk-NR5R6, -O-Alk-CN, -O-(CH2)n-Ph, -O-Alk-CO-NR5R6, -CO-NH-(CH2)m-COOR7, -CO-NH-Alk· το R2 αντιπροσωπεύει Η, αλκυλ(C1-C5), αλογονίδιο αλκυλίου (C1-C5), κυκλοαλκυλ (C3-C6) ή ενδεχομένως υποκατεστημένο φαινυλ· το Α αντιπροσωπεύει -CO-, -SO-, ή -SO2-, το R3 και το R4 ταυτόσημα ή διαφορετικά αντιπροσωπεύουν το καθένα ξεχωριστά Η, αλκοξυ(C1-C5), αμινο, καρβοξυ, αλκοξυκαρβονυλ(C2-C6), -ΟΗ, νιτρο, υδροξυαμινο, -Alk-COOR7, -NR5R6, -NH-Alk-COOR7, -NH-COO-Alk, -N(R11)-SO2-Alk-NR9R10, -N(R11)-SΟ2-Alk, -N(R11)-Alk-NR5R6, -N(R11)-CO-Alk-NR9R10, -N(R11)-CO-Alk, -N(R11)-CO-CF3, -NH-Alk-HetN, -O-Alk-NR9R10,-O-Alk-CO-NR5R6, -O-Alk-HetN, ή το R3 και το R4 σχηματίζουν μαζί έναν ακόρεστο ετερόκυκλο ο οποίος αποτελείται από 5 έως 6 αλυσίδες, ενδεχομένως υπό την μορφή ενός εκ των φαρμακευτικώς αποδεκτών τους αλάτων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0401094A FR2865934B1 (fr) | 2004-02-05 | 2004-02-05 | Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne |
EP05717556A EP1713543B1 (fr) | 2004-02-05 | 2005-02-04 | Utilisation de derives d'indolizine 1,2,3 substitues pour le traitement de maladies liees a une angiogenese pathologique choroidienne |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109669T1 true CY1109669T1 (el) | 2014-08-13 |
Family
ID=34778525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091101327T CY1109669T1 (el) | 2004-02-05 | 2009-12-09 | Χρηση υποκατεστημενων παραγωγων της ινδολιζινης 1,2,3 για τη θεραπεια νοσων που σχετιζονται με μια παθολογικη χοριοειδη αγγειογενεση |
Country Status (21)
Country | Link |
---|---|
US (1) | US8034828B2 (el) |
EP (1) | EP1713543B1 (el) |
JP (1) | JP5268258B2 (el) |
KR (1) | KR101199730B1 (el) |
CN (1) | CN1917922B (el) |
AT (1) | ATE448003T1 (el) |
AU (1) | AU2005216671B2 (el) |
BR (1) | BRPI0507509A (el) |
CA (1) | CA2553895C (el) |
CY (1) | CY1109669T1 (el) |
DE (1) | DE602005017581D1 (el) |
DK (1) | DK1713543T3 (el) |
ES (1) | ES2335900T3 (el) |
FR (1) | FR2865934B1 (el) |
HK (1) | HK1101065A1 (el) |
HR (1) | HRP20100030T1 (el) |
IL (1) | IL177088A (el) |
PL (1) | PL1713543T3 (el) |
PT (1) | PT1713543E (el) |
SI (1) | SI1713543T1 (el) |
WO (1) | WO2005082457A2 (el) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
SG158147A1 (en) * | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
EP2270043A1 (en) | 2009-07-03 | 2011-01-05 | Sanofi-Aventis | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
FR2962438B1 (fr) * | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'indolizines, procedes de preparation et application en therapeutique |
FR2962437B1 (fr) | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
-
2004
- 2004-02-05 FR FR0401094A patent/FR2865934B1/fr not_active Expired - Fee Related
-
2005
- 2005-02-04 CA CA2553895A patent/CA2553895C/fr not_active Expired - Fee Related
- 2005-02-04 DK DK05717556.4T patent/DK1713543T3/da active
- 2005-02-04 BR BRPI0507509-2A patent/BRPI0507509A/pt not_active IP Right Cessation
- 2005-02-04 EP EP05717556A patent/EP1713543B1/fr active Active
- 2005-02-04 AU AU2005216671A patent/AU2005216671B2/en not_active Ceased
- 2005-02-04 AT AT05717556T patent/ATE448003T1/de active
- 2005-02-04 WO PCT/FR2005/000253 patent/WO2005082457A2/fr active Application Filing
- 2005-02-04 PT PT05717556T patent/PT1713543E/pt unknown
- 2005-02-04 DE DE602005017581T patent/DE602005017581D1/de active Active
- 2005-02-04 PL PL05717556T patent/PL1713543T3/pl unknown
- 2005-02-04 JP JP2006551884A patent/JP5268258B2/ja active Active
- 2005-02-04 CN CN2005800041509A patent/CN1917922B/zh not_active Expired - Fee Related
- 2005-02-04 SI SI200530900T patent/SI1713543T1/sl unknown
- 2005-02-04 KR KR1020067017920A patent/KR101199730B1/ko not_active IP Right Cessation
- 2005-02-04 ES ES05717556T patent/ES2335900T3/es active Active
-
2006
- 2006-07-25 IL IL177088A patent/IL177088A/en not_active IP Right Cessation
-
2007
- 2007-08-13 HK HK07108749.0A patent/HK1101065A1/xx not_active IP Right Cessation
-
2008
- 2008-08-29 US US12/201,075 patent/US8034828B2/en active Active
-
2009
- 2009-12-09 CY CY20091101327T patent/CY1109669T1/el unknown
-
2010
- 2010-01-18 HR HR20100030T patent/HRP20100030T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
ATE448003T1 (de) | 2009-11-15 |
PL1713543T3 (pl) | 2010-04-30 |
US8034828B2 (en) | 2011-10-11 |
CN1917922A (zh) | 2007-02-21 |
IL177088A (en) | 2010-12-30 |
JP2007520534A (ja) | 2007-07-26 |
HK1101065A1 (el) | 2007-10-05 |
CA2553895A1 (fr) | 2005-09-09 |
US20090030034A1 (en) | 2009-01-29 |
IL177088A0 (en) | 2006-12-10 |
FR2865934B1 (fr) | 2006-05-05 |
FR2865934A1 (fr) | 2005-08-12 |
DK1713543T3 (da) | 2010-03-22 |
CA2553895C (fr) | 2013-04-02 |
ES2335900T3 (es) | 2010-04-06 |
SI1713543T1 (sl) | 2010-03-31 |
EP1713543B1 (fr) | 2009-11-11 |
PT1713543E (pt) | 2009-12-15 |
DE602005017581D1 (de) | 2009-12-24 |
EP1713543A2 (fr) | 2006-10-25 |
WO2005082457A2 (fr) | 2005-09-09 |
AU2005216671B2 (en) | 2010-09-16 |
JP5268258B2 (ja) | 2013-08-21 |
CN1917922B (zh) | 2013-06-12 |
KR101199730B1 (ko) | 2012-11-08 |
WO2005082457A3 (fr) | 2005-11-10 |
BRPI0507509A (pt) | 2007-06-26 |
KR20070034986A (ko) | 2007-03-29 |
HRP20100030T1 (hr) | 2010-03-31 |
AU2005216671A1 (en) | 2005-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109669T1 (el) | Χρηση υποκατεστημενων παραγωγων της ινδολιζινης 1,2,3 για τη θεραπεια νοσων που σχετιζονται με μια παθολογικη χοριοειδη αγγειογενεση | |
BRPI0513750A (pt) | 2-fenilamino-benzamidas-5-substituìdas como inibidoras de mek | |
NO20062905L (no) | Nye hydroksaminsyreestere og farmasoytisk anvendelse derav | |
SE0202462D0 (sv) | Novel use | |
CY1107853T1 (el) | Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων | |
PE20030581A1 (es) | Composiciones polimeras de liberacion controlada de compuestos que promueven el crecimiento oseo | |
CR20230517A (es) | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades | |
MX2022015703A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf. | |
ATE357453T1 (de) | Comt-inhibitoren | |
EA200971086A1 (ru) | Фармацевтические композиции и способ лечения шизофрении | |
NO20072684L (no) | Konjugater med anti-inflammatorisk aktivitet | |
ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
WO2007099302A3 (en) | Methods of maintaining oral health in animals using morpholine derivatives | |
CY1109546T1 (el) | Φαρμακο για την προληψη η θεραπεια της συχνουριας η της ουρικης ακρατειας | |
RU2007141412A (ru) | Пиридилдиметилсульфоновое производное | |
DE60127535D1 (de) | Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation | |
MY164375A (en) | Phenylketone carboxylate compounds and pharmaceutical uses thereof | |
EA200601514A1 (ru) | Производные пиперазинмочевины для лечения эндометриоза | |
MX2022014523A (es) | Derivado de piridina y aplicacion del mismo. | |
DE60126199D1 (de) | Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen | |
RU2009138028A (ru) | Новое профилактическое и/или лекарственное средство против невропатической боли | |
HK1080768A1 (en) | Use of epothilone derivatives for the treatment ofhyperparathyroidism | |
TW200635575A (en) | Use of substituted cyclopropane acid derivatives for producing medicaments for treating the metabolic syndrome |